Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anlon HealthcareNSE:AHCL +0.51%19 12-1 Month Momentum % is 60.09% as of Sep. 05, 2026. GuruFocus rates NSE:AHCL with a GF Score™ of 19/100. The stock has 5 warning signs investors should review. Among 1,015 Drug Manufacturers companies, Anlon Healthcare ranks worse than 98522.07% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-05), Anlon Healthcare's 12-1 Month Momentum % is 60.09%.
The industry rank for Anlon Healthcare's 12-1 Month Momentum % or its related term are showing as below:
NSE:AHCL's 12-1 Month Momentum % is not ranked
in the Drug Manufacturers industry.
Industry Median: -15.23
vs NSE:AHCL: 60.09
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Anlon Healthcare 12-1 Month Momentum % Related Terms
NSE:AHCL vs ZTS: 12-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Anlon Healthcare's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anlon Healthcare 12-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anlon Healthcare's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Anlon Healthcare's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anlon Healthcare (NSE:AHCL) has a 12-1 Month Momentum % of 60.09% as of Sep. 05, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Anlon Healthcare and its competitors. According to the industry distribution chart, Anlon Healthcare ranks #999999 out of 1015 companies in the Drug Manufacturers industry.
Is Anlon Healthcare's 12-1 Month Momentum % too high?
Anlon Healthcare's current 12-1 Month Momentum % is 60.09%. Based on the distribution chart, Anlon Healthcare ranks #999999 out of 1015 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Anlon Healthcare has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Anlon Healthcare's 12-1 Month Momentum % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Anlon Healthcare ranks #999999 out of 1015 companies for 12-1 Month Momentum %. This places Anlon Healthcare in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Drug Manufacturers company?
A good 12-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Anlon Healthcare and its competitors. Anlon Healthcare's current 12-1 Month Momentum % is 60.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anlon Healthcare stock overvalued right now?
Anlon Healthcare (NSE:AHCL) has a current 12-1 Month Momentum % of 60.09%. The current 12-1 Month Momentum % is 60.09%. Anlon Healthcare's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Anlon Healthcare (NSE:AHCL), the current 12-1 Month Momentum % is 60.09% as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anlon Healthcare Ltd is a chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products. Its products spans across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API.
19GF Score
Get the complete analysis for NSE:AHCL
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AHCL has been successfully added to your 
